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ICD Shocks in Cardiac Sarcoidosis. Background: An implantable cardioverter defibrillator (ICD)
is indicated for some patients with cardiac sarcoidosis (CS) for prevention of sudden death. However,
there are little data regarding the event rates of ICD therapies in these patients. We sought to identify the
incidence and characteristics of ICD therapies in this patient population.
Methods: We performed a cohort study of patients with ICDs at 3 institutions. Cases were those patients
with CS and an ICD implanted for primary or secondary prevention of sudden death. Additionally, we
included a comparison with historical controls of ICD therapy rates reported in clinical trials evaluating
the ICD for primary and secondary prevention of sudden death.
Results: Of the 112 CS subjects identified, 36 (32.1%) received appropriate therapies for ventricular
tachyarrhythmias (VT) over a mean follow-up period of 29.2 months. VT storm (>3 episodes in 24 hours)
occurred in 16 (14.2%) CS subjects. Inappropriate therapies occurred in 13 CS subjects (11.6%). Covariates
associated with appropriate ICD therapies included left ventricular ejection fraction (LVEF) <55% (OR
6.52 [95% CI 2.43–17.5]), right ventricular dysfunction (OR 6.73 [95% CI 2.69–16.8]), and symptomatic
heart failure (OR 4.33 [95% CI 1.86–10.1]).
Conclusions: In our cohort of patients with CS and ICDs, almost one-third receive appropriate thera-
pies. This may be due to a myocardial inflammatory process leading to increased triggered activity and
subsequent scarring leading to reentrant tachyarrhythmias. Adjusted predictors of ICD therapies in this
population include left or right ventricular dysfunction. (J Cardiovasc Electrophysiol, Vol. 23, pp. 925-929,
September 2012)
cardiac sarcoid, cardiomyopathy, heart failure, implantable cardioverter defibrillator, ventricular tachycardia
Background
Sarcoidosis is a granulomatous disorder affecting multiple
organ systems including the heart with a lifetime prevalence
of 0.85–2.4% depending on ethnicity.1 Cardiac involvement
is diagnosed antemortem in approximately 5% of systemic
sarcoidosis patients but is seen in up to 25% of patients
with systemic sarcoidosis on autopsy.2 The leading causes
of death in patients with sarcoidosis are cardiac arrhythmias,
progressive heart failure, and progressive respiratory failure.3
Cardiac involvement accounts for 13–25% of all deaths in
patients with sarcoidosis.2 Sudden death is the most common
manifestation of cardiac sarcoidosis, involving more than
60% of patients.4
The mechanism and characteristics of the ventricular ar-
rhythmias in cardiac sarcoidosis have previously been de-
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scribed. Cardiac involvement occurs initially with inflam-
mation and granuloma formation followed by scarring.5 The
initial inflammation can lead to triggered ventricular arrhyth-
mias with subsequent scarring resulting in the substrate for
reentrant monomorphic ventricular tachycardia.
Because of the waxing and waning inflammatory nature of
the disease process, it is unclear if implantable cardioverter
defibrillator (ICD) therapy is effective in the prevention of
sudden cardiac death. Several reports have demonstrated the
potential for life threatening arrhythmias associated with car-
diac sarcoidosis and prophylactic ICD implantation is recom-
mended as a class IIa indication.6 Furthermore, it is possible
that inflammation can result in ventricular arrhythmias and
that the incidence of ICD storm may be more common. We
hypothesize that ICD therapies would be common in patients
with cardiac sarcoidosis and we hypothesize that VT storm
(defined as 3 or more therapies in 24 hours) will also be more
common. We sought to identify the incidence and character-
istics of ICD therapy in patients with cardiac sarcoidosis.
Methods
Study Population and Data Collection
The study cohort consisted of patients referred to the Uni-
versity of Colorado, University of Michigan, and Univer-
sity of Chicago for evaluation of the presence of cardiac
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sarcoidosis. Patients diagnosed with cardiac sarcoidosis who
subsequently received an ICD were included in the cohort.
Data collection was performed retrospectively according
to a standardized protocol. All patients included in the cohort
had biopsy proven extracardiac sarcoidosis.
Criteria for Detection of Cardiac Sarcoidosis
A modification of the Japanese Ministry of Health and
Welfare criteria for diagnosis of cardiac sarcoidosis (to in-
clude cardiac MRI and electrophysiologic testing) was used
for the diagnosis of cardiac sarcoidosis. Patients were diag-
nosed with cardiac sarcoidosis if 2 or more of the following
studies indicated cardiac involvement:
• ECG and Outpatient Telemetry: Left axis deviation, VT,
frequent premature ventricular contractions (PVCs), or ab-
normal Q waves or ST segment abnormalities (in absence
of prior myocardial infarction), bundle branch block or
advanced atrio-ventricular (AV) block.
• Echo: Regional wall motion abnormalities, segmental thin-
ning, or dilated left ventricle
• Nuclear: Perfusion defects (without coronary disease) on
single photon emission computed tomography or active
inflammation observed on positron emission tomography
• Cardiac Catheterization (when available): Elevated intra-
cardiac pressures or low cardiac output
• Cardiac MRI: Delayed intramyocardial contrast enhance-
ment
• Electrophysiologic Study (when available): Inducible
monomorphic ventricular tachycardia with up to triple ex-
trastimulation or inducible polymorphic ventricular tachy-
cardia or ventricular fibrillation with up to double ex-
trastimulation; abnormal right ventricular voltage (<1.5
mV) with electroanatomical mapping
• Histology on Cardiac Biopsy: Nonspecific interstitial fi-
brosis or cellular infiltration with myocardial biopsy.
ICD Implantation and Clinical Follow-Up
All patients underwent routine ICD implantation using
standard techniques. Perioperative antibiotics were standard,
and all patients underwent defibrillation threshold testing at
the time of implantation unless contraindicated. If the device
was not tested at implant, the patient returned within 3 months
for defibrillation threshold testing. Patients were followed
with routine wound and device checks within the first 2 weeks
after implant, and the devices were interrogated at 3-month
intervals afterward. Device interrogation data were stored in
the Paceart data software system and in hard copy on site.
Device programming was at the discretion of the implanting
physician.
When possible, assessment of ventricular function was by
cardiac MRI. Once the ICD was implanted or for patients
who did not have a cardiac MRI, assessment of ventricular
function was by either echo or nuclear imaging. Right ven-
tricular dysfunction was defined as a right ventricular ejection
fraction (RVEF) <45% by MRI or reported RV dysfunction
by echo or nuclear imaging.
Classification of ICD Therapies
ICD therapies were reviewed and classified based upon
the stored device electrograms and clinical scenario by an
electrophysiologist. Appropriate therapies were defined as
device delivered anti-tachycardia pacing (ATP) or shocks for
TABLE 1
Clinical Characteristics of Patients with Cardiac Sarcoidosis (CS) and an
Implantable Cardioverter Defibrillator (ICD)
Cardiac Sarcoidosis Cohort
N = 112 112
Age (years) 52.6 ± 11.4
Male gender 63 (56.3%)
LVEF mean 44.9 ± 17.1%
RV dysfunction 54 (48.2%)





Renal insufficiency 22 (19.6%)
Complete heart block 17 (15.2%)
Right bundle branch block 30 (26.8%)
VT or VF. Inappropriate therapies were ATP or shocks re-
sulting from supraventricular arrhythmias (including atrial
fibrillation and flutter), T wave oversensing, or lead noise.
ICD storm was defined as 3 or more appropriate ICD thera-
pies in a 24-hour period.
Statistical Analysis
Results are expressed as mean ± standard deviation. The
Pearson chi-square test was used to compare clinical charac-
teristics between patients with and without cardiac sarcoido-
sis. The one-way analysis of variance (ANOVA) was used
for continuous covariates. Multivariable logistic regression
analysis was used to adjust for possible confounding. The
variables included in the multivariable model were variables
that affected the crude odds ratio (OR) by more than 10%.
The variables used in the multivariable model were age, sex,
left ventricular ejection fraction, right ventricular dysfunc-
tion, New York Heart Association functional class, history
of hypertension, coronary disease, diabetes mellitus, or renal
insufficiency. Statistical analyses were performed using the
SPSS (version 18.0; SPSS Inc, Chicago, IL, USA) statistical
software program, and statistical significance was defined as
a two-sided P value less than 0.05.
Results
Clinical Characteristics of Study Cohort
Table 1 displays the clinical characteristics of the study
cohort. We identified 112 ICD patients with cardiac sarcoido-
sis that were followed for a mean of 29.2 months. The mean
age of the cohort was 52.6 years, and 53% were men. The
mean left ventricular ejection fraction was 44.9% and right
ventricular dysfunction was noted in 48%. There were 5
patients with coronary artery disease, 22 with diabetes mel-
litus, 43 with hypertension, 31 with hyperlipidemia, and 22
with chronic renal insufficiency (Tables 1 and 2). Seventeen
patients had a history of complete heart block, and 30 pa-
tients demonstrated right bundle branch block. There were
6 patient deaths among the cohort. Four patients underwent
cardiac transplantation.
Incidence of Appropriate and Inappropriate ICD Therapy
Of the 112 subjects with cardiac sarcoidosis, 36 (32.1%)
received appropriate therapies for ventricular tachyarrhyth-
mias (VT). ICD storm, defined as 3 or more appropriate ICD
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TABLE 2
Comparison of Clinical Characteristics of Patients with CS with and without ICD Therapies
Cardiac Sarcoidosis Cohort No Therapies Any Therapy P Value Appropriate Therapy P Value
N = 112 66 46 (41.1%) 36 (32.1%)
Age (years) 55.1 ± 11.3 48.9 ± 10.7 0.004 49.5 ± 11.1 0.052
Male gender 34 (51.5%) 29 (63%) 0.25 26 (72.2%) 0.025
LVEF mean 50.6 ± 14.1 37.3 ± 18 <0.01 32.2 ± 16.5 <0.01
RV dysfunction 24 (36.4%) 30 (65.2%) <0.01 28 (77.8%) <0.01
NYHA class II—IV 20 (30.3%) 28 (60.9%) <0.01 24 (66.7%) <0.01
CAD 4 (6.1%) 1 (2.2%) 0.65 1 (2.8%) 1
Diabetes 11 (16.7%) 11 (23.9%) 0.35 9 (25%) 0.32
HTN 28 (42.4%) 15 (32.6%) 0.33 10 (27.8%) 0.15
Hyperlipidemia 18 (27.3%) 13 (28.3%) 1 8 (22.2%) 0.5
Renal insufficiency 13 (19.7%) 9 (19.6%) 1 9 (25%) 0.32
Complete heart block 10 (15.2%) 8 (17.4%) 1 7 (19.4%) 0.41
Right bundle branch block 21 (31.8%) 10 (21.7) 1 9 (25%) 0.32
Cardiac Sarcoidosis Cohort Inappropriate Therapy P Value VT Storm P Value
N = 112 13 (11.6%) 16 (14.2%)
Age (years) 49.2 ± 11.1 0.25 47 ± 9.4 0.035
Male gender 5 (38.5%) 0.24 12 (75%) 0.17
LVEF mean 50.2 ± 14 0.24 34 ± 16.8 <0.01
RV dysfunction 7 (53.8%) 0.77 12 (75%) 0.029
NYHA class II–IV 4 (30.8%) 0.39 9 (56.3%) 0.28
CAD 0 1 0 1
Diabetes 3 (23.1%) 0.72 4 (25%) 0.52
HTN 4 (30.8%) 0.76 6 (37.5%) 0.55
Hyperlipidemia 5 (38.5%) 0.34 3 (18.8%) 1
Renal insufficiency 2 (15.4%) 1 3 (18.8%) 1
Complete heart block 2 (15.4%) 1 5 (31.3%) 0.54
Right bundle branch block 3 (23.1%) 0.72 5 (31.3%) 0.54
Figure 1. Incidence of ICD therapies, including VT storm, in patients with
cardiac sarcoidosis.
therapies in 24 hours, occurred in 16 of the 112 (14.3%)
of the cardiac sarcoidosis patients. Thirteen patients in the
cohort received inappropriate therapy (11.6%) (Fig. 1).
In an unadjusted analysis there were 3 predictors of appro-
priate ICD therapies identified. Left ventricular dysfunction
as assessed by either MRI or echocardiogram was associated
with an OR of 6.52 (95% CI 2.43–17.5, P < 0.01). Right ven-
tricular dysfunction as assessed by MRI or echocardiogram
was associated with an OR of 6.73 (95% CI 2.69–16.8, P <
0.01). Symptomatic heart failure (New York Heart Associ-
ation functional class II–IV) was associated with an OR of
4.33 (95% CI 1.86–10.1, P < 0.01). Of the 36 patients who
received appropriate ICD therapy, only 1 patient had normal
right and left ventricular function.
After multivariable adjustment, left and right ventricular
dysfunction remained significant predictors of future ICD
therapies (adjusted OR for LV dysfunction 6.52 [95% CI
2.43–17.5, P < 0.01], adjusted OR for RV dysfunction 5.64
[95% CI 2.19–14.6, P < 0.01]). After multivariable adjust-
ment, symptomatic heart failure was no longer significantly
associated with appropriate ICD therapies (OR 1.89 [95% CI
0.69–5.15], P = 0.21).
ICD Storm in Patients with Cardiac Sarcoidosis
ICD storm, defined as 3 or more appropriate ICD therapies
in 24 hours, occurred in 16 of the 112 (14.3%) of the cardiac
sarcoidosis patients. Predictors of ICD storm included left
ventricular dysfunction (OR 6.71 [95% CI 1.45–31.2], P =
0.015) and right ventricular dysfunction (OR 3.86 [95% CI
1.16–12.8], P = 0.03).
Prediction of Ventricular Arrhythmias in Patients with
Cardiac Sarcoidosis and Primary versus Secondary
Prevention Devices
Of the 112 patients with cardiac sarcoidosis and an ICD,
83 (74.1%) were implanted for primary prevention. Among
this subset, 23 (27.7%) received appropriate ICD therapy for
VT or VF over a mean follow-up period of 30.6 months. Of
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the primary prevention subset, no patients with normal right
and left ventricular function received an appropriate therapy.
The mean left ventricular ejection fraction among the sec-
ondary prevention subset was 40.6% and among the primary
prevention subset was 46.4%. Right ventricular dysfunction
was present in 53.6% of the secondary prevention subset and
in 46.4% of the primary prevention subset. In comparison
with the patients with primary prevention devices, a previous
history VT/VF was not a significant predictor of appropriate
ICD therapies (OR 1.36 [CI 0.53–3.48]).
Discussion
Study Results
This study details our experience with cardiac sarcoido-
sis and ICDs at 3 institutions with a relatively large pop-
ulation of patients with cardiac sarcoidosis. We found that
ICD therapies are frequent in patients with cardiac sarcoido-
sis. Ventricular dysfunction appears to be a strong predictor
of ventricular arrhythmias. This is likely a reflection of a
more advanced disease state with either transient inflamma-
tion with associated contractile dysfunction, or ventricular
scarring with associated reentrant arrhythmias.
Further, the rate of ICD therapies in our cohort of car-
diac sarcoidosis is greater than reported rates from historical
controls. In the large randomized trials PREPARE and SCD-
HeFT, annualized ICD therapy rates of 5.4% and 5.1% were
reported, respectively.7,8 In the secondary prevention trial
SMASH-VT, an annualized ICD therapy rate of 16.5% was
reported.9 The annualized appropriate ICD therapy rate in our
cohort was 13.2%. Among the primary prevention subgroup
the annualized ICD therapy rate was 10.7%, and among the
secondary prevention subgroup the annualized ICD therapy
rate was 21%.
Reports of ICD therapy rates from other infiltrative car-
diomyopathies are also similarly high. ICD therapy rates in
arrhythmogenic right ventricular cardiomyopathy range from
24% to 74% at 5 years.10
We also observed that ICD storm was common in our co-
hort of cardiac sarcoidosis, occurring in 14.3% of the cardiac
sarcoidosis patients.
Use of Primary Prevention ICDs in Patients with Cardiac
Sarcoidosis
Cardiac sarcoidosis is a rare disease that is often difficult
to diagnose and there is little known regarding the poten-
tial role of the implantable defibrillator for prevention of
sudden death. In patients with sarcoidosis, ICD therapy can
be used as a component of an aggressive primary preven-
tion strategy when cardiac involvement is established. For
sarcoidosis patients who present with sustained ventricular
arrhythmias and are diagnosed with cardiac involvement,
ICD implantation is standard practice. To date, there have
been no prospective studies comparing ICD therapy with an-
tiarrhythmic drugs or immunosuppression. This report is the
largest experience with a primary and secondary prevention
ICD strategy. As one might expect, the rate of ICD therapies
is very high among the patients with a secondary prevention
device. Interestingly, even among patients with a primary
prevention device the incidence of appropriate ICD thera-
pies was 11.3% annually. This is a higher annualized rate
than reported in other large primary prevention ICD trials.
The reported annualized ICD therapy rate among patients
with arrhythmogenic right ventricular cardiomyopathy and
primary prevention device is 4.9%.11
Potential Mechanisms for Ventricular Tachycardia
As described in the introduction, there is evidence for
multiple mechanisms for VT in cardiac sarcoidosis. The in-
flammatory nature of the granulomas in sarcoidosis may lead
to increased automatic ventricular activity. The subsequent
scar formation is then the substrate for reentrant ventricular
arrhythmias. This combination of underlying mechanisms
makes treating the arrhythmias challenging and is possibly
the reason for the relatively high rate of therapies observed
in this cohort.
Potential Limitations
The limitations of observational research must be consid-
ered in this study. One such limitation involves the certainty
of the cardiac sarcoidosis diagnosis in our cohort. We used
a clinical diagnostic criteria scheme that has not been corre-
lated with autopsy studies proving a histologic diagnosis. In
addition, there remains the possibility of false positive radio-
logical studies leading to an inaccurate diagnosis. However,
we believe that corroborated abnormal cardiac findings in
patients with extra-cardiac sarcoidosis strongly suggest car-
diac involvement. If there were a misclassification bias, then
this bias would be toward a lower rate of appropriate ICD
therapy as patients without cardiac sarcoidosis would not be
expected to have ventricular arrhythmias.
Another limitation of the study involves the relatively
small number of events reducing our ability to evaluate po-
tential confounders in the multivariable analysis. Our com-
parison to historical control groups is not matched by age,
gender, or clinical features; however, we believe that an
unmatched comparison is useful to clinicians who may be
faced with the clinical question of ICD implantation in these
patients.
Data regarding ICD programming, VT cycle length, or
treatment for ventricular fibrillation were not available for
all patients across the 3 study sites and were not included
in our analysis. Similarly, data regarding ICD implantation
complication rates, background medical therapy, and nonsus-
tained ventricular arrhythmias were not uniformly collected
and therefore were not included in the analysis. However,
while all of these covariates may influence the rate of appro-
priate ICD therapy, we believe that these variables alone do
not explain the high rate of ICD therapy seen in our cohort.
The clinicians responsible for the care of these patients at the
3 participating sites are all experienced electrophysiologists
who routinely program devices to prevent unnecessary ICD
therapy.
Conclusions
ICD therapies in patients with cardiac sarcoidosis are
common. The rates of appropriate and inappropriate ther-
apies are similar to those seen in other populations of high-
risk patients. The notable exception of VT storm appears to
be more common in the cardiac sarcoidosis cohort. Based
on the findings of this study we recommend an aggres-
sive prospective screening approach for patients with biopsy
proven extra-cardiac sarcoidosis in whom cardiac involve-
ment is suspected.
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